Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Marketsascendis pharmanovo nordisktransconobesity

Ascendis regains full rights to TransCon metabolic programs from Novo

The Danish biotech takes back its cardiometabolic assets after Novo Nordisk exits the partnership.

TR
By Tom Reyes · Markets Editor
Sep 15 06:58 ETSource: TipRanks

The wire

  1. 01Ascendis Pharma reclaimed full rights to TransCon metabolic and cardiovascular programs after the Novo Nordisk split.
  2. 02Gives Ascendis control of assets it had partnered to a dominant obesity player.
  3. 03Ascendis' funding and development path for the reclaimed programs is unclear.

From the source

Ascendis Pharma Regains Full Rights to TransCon Metabolic and Cardiovascular Programs After Novo Nordisk Split

Read at news.google.com
Source URL https://news.google.com/rss/articles/CBMi9AFBVV95cUxQYTA1TkZNZHprcDhQaXIwMWJEemZkTTlsZWYwc3dpTFA5Rnc4akl1RmlDOHJsS0dXa1hpeDZjMkNwN1g0aHc0WmF4TkNad25EejF2R2NxM1daOUwycWR3TEFSb3dvODVqTmZ5VUw1SFNTSEhES3FZeThOaGJaVlFoMWkwd1VvbWpMV1M0eUFPQncxYjU0ZUFidEFMTXhwb1ExUGpyODdyNHAwVkduY3d5QmI1NW5DdDJNcWhkSUJFTDF3ejV2WlRsaU5MbTlCT005NllxVmRueHo1SnJzVzRISWRoNkRfRG43Ujl3Tm9ZWFlOd3Vn?oc=5